Similar articles for PMID: 23550255

Year	Number of Results
2000	1
2001	2
2002	1
2003	3
2004	3
2005	3
2006	6
2007	5
2008	4
2010	7
2011	8
2012	14
2013	18
2014	19
2015	14
2016	10
2017	7
2018	17
2019	11
2020	11
2021	3
2022	3
2024	0

1

Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis.

Olivieri I, D'Angelo S, Palazzi C, Leccese P, Nigro A, Padula A. Olivieri I, et al. Reumatismo. 2013 Mar 28;65(1):1-3. doi: 10.4081/reumatismo.2013.1. Reumatismo. 2013. PMID: 23550255 No abstract available.

2

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J; Assessment of SpondyloArthritis international Society. van der Heijde D, et al. Ann Rheum Dis. 2011 Jun;70(6):905-8. doi: 10.1136/ard.2011.151563. Ann Rheum Dis. 2011. PMID: 21540200

3

Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.

Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G. Gremese E, et al. Rheumatology (Oxford). 2014 May;53(5):875-81. doi: 10.1093/rheumatology/ket433. Epub 2014 Jan 9. Rheumatology (Oxford). 2014. PMID: 24407233

4

Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.

Poddubnyy D, Rudwaleit M. Poddubnyy D, et al. Expert Opin Biol Ther. 2013 Nov;13(11):1599-611. doi: 10.1517/14712598.2013.839653. Epub 2013 Sep 27. Expert Opin Biol Ther. 2013. PMID: 24074224 Review.

5

Certolizumab pegol in axial spondyloarthritis.

Song IH, Rudwaleit M. Song IH, et al. Expert Rev Clin Immunol. 2013 Dec;9(12):1161-72. doi: 10.1586/1744666X.2013.858859. Expert Rev Clin Immunol. 2013. PMID: 24215406 Review.

6

Absence of radiographic progression at two years in a cohort of patients with non-radiographic axial spondyloarthritis treated with TNF-α blockers.

Almirall M, López-Velandia JG, Maymó J. Almirall M, et al. Reumatol Clin. 2014 Mar-Apr;10(2):134-5. doi: 10.1016/j.reuma.2013.04.003. Epub 2013 Jul 1. Reumatol Clin. 2014. PMID: 23827199 Free article. English, Spanish. No abstract available.

7

[New synthetic and biologic treatments for spondylarthritis].

Zufferey P. Zufferey P. Rev Med Suisse. 2016 Mar 9;12(509):512, 514-6. Rev Med Suisse. 2016. PMID: 27089641 Review. French.

8

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Gao X, et al. J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11. J Med Econ. 2012. PMID: 22563743 Free article.

9

The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.

Troppmann L, Karsh J; Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada. Troppmann L, et al. J Rheumatol. 2008 Apr;35(4):658-61. Epub 2008 Feb 15. J Rheumatol. 2008. PMID: 18278833

10

Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS; Spondyloarthritis Research Consortium of Canada (SPARCC). Maksymowych WP, et al. J Rheumatol. 2003 Jun;30(6):1356-63. J Rheumatol. 2003. PMID: 12784417 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year